GD
GDRX.US Goodrx Holdings Inc
- Market cap
- USD 1.21B
- P/E
- 71.2x
- P/B
- 1.85x
- ROE
- 3.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GDRX.US undervalued?
Graham numberGDRX.US trades 141.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Goodrx Holdings Inc fundamental analysis
No fundamental analysis for Goodrx Holdings Inc yet.
Goodrx Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Goodrx Holdings Inc
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions,…
Full company profileGoodrx Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Goodrx Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 99.4M | 157M | 250M | 388M | 551M | 745M | 767M | 750M | 792M | 797M | 789M |
| Gross Profit | 89.1M | 145M | 243M | 374M | 521M | 699M | 701M | 683M | 744M | 739M | 663M |
| Operating Income | 18.9M | 50.3M | 77.3M | 140M | -276M | 13.4M | 1.74M | -27.0M | 65.8M | 87.5M | 86.4M |
| EBITDA | 28.0M | 59.4M | 84.3M | 146M | -257M | 48.0M | 65.2M | 109M | 154M | 184M | 169M |
| Net Income | -7.77M | 8.84M | 43.8M | 66.0M | -294M | -25.3M | -32.8M | -8.87M | 16.4M | 30.4M | 19.4M |
| EPS | -0.02 | 0.02 | 0.12 | 0.18 | -1.07 | -0.06 | -0.08 | -0.02 | 0.04 | 0.09 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 296M | 287M | 315M | 387M | 1.47B | 1.61B | 1.60B | 1.59B | 1.39B | 1.40B | 2.34B |
| Total Liabilities | 46.1M | 136M | 1.48B | 1.47B | 759M | 776M | 790M | 827M | 663M | 788M | 1.70B |
| Shareholders' Equity | 8.11M | -86.2M | -1.16B | -1.09B | 711M | 832M | 815M | 762M | 725M | 616M | 648M |
| Cash & Short-term Investments | 23.6M | 17.5M | 34.6M | 26.1M | 969M | 941M | 757M | 672M | 448M | 262M | 296M |
| Total Debt | 46.1M | 136M | 722M | 711M | 705M | 702M | 717M | 711M | 543M | 543M | 539M |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | 45.3M | 83.3M | 131M | 179M | 147M | 138M | 184M | 168M | 185M |
| Capital Expenditure | - | - | 3.46M | 5.75M | 35.8M | 34.5M | 55.2M | 55.8M | 70.3M | 3.52M | 44.0M |
| Free Cash Flow | - | - | 41.8M | 77.5M | 95.5M | 144M | 91.6M | 82.5M | 114M | 164M | 141M |
| Ratios | |||||||||||
| ROE | -95.9% | - | - | - | -41.3% | -3.0% | -4.0% | -1.2% | 2.3% | 4.9% | 3.0% |
| ROA | -2.6% | 3.1% | 13.9% | 17.1% | -20.0% | -1.6% | -2.0% | -0.6% | 1.2% | 2.2% | 0.8% |
| Net Profit Margin | -7.8% | 5.6% | 17.6% | 17.0% | -53.3% | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% | 2.5% |
| Debt to Equity | 5.68x | - | - | - | 0.99x | 0.84x | 0.88x | 0.93x | 0.75x | 0.88x | 0.83x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Goodrx Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.00 | 0.00 | - |
| 2022 | - | - | - |
| 2021 | USD 22.7M | 0.06 | - |
| 2020 | USD 78.7M | 0.29 | - |
| 2019 | - | - | - |
| 2018 | USD 1.35B | 3.71 | 3,074.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Goodrx Holdings Inc
- Insiders 12.95%
- Institutions 55.41%
- Public & others 31.64%
- Shares outstanding 107M
- Free float 93.5M
Top funds holding GDRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.93M | 0.86% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap Value I | 1.35M | 0.40% | +76.27% | Sep 2026 |
| Vanguard Strategic Equity Inv | 1.26M | 0.37% | 0.00% | Sep 2026 |
| Vanguard Small Cap Index | 1.02M | 0.30% | +0.09% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 667K | 0.20% | +2.59% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 486K | 0.14% | +0.24% | Oct 2026 |
| Dimensional US Small Cap Value ETF | 485K | 0.14% | +0.18% | Sep 2026 |
| Northern Small Cap Value | 484K | 0.14% | +18.42% | Sep 2026 |
| Dimensional US Targeted Value ETF | 451K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 445K | 0.13% | -7.92% | Sep 2026 |
| SEI Small/Mid Cap Equity A (SIIT) | 396K | 0.12% | 0.00% | Oct 2026 |
| DFA U.S. Targeted Value I | 341K | 0.10% | +39.13% | Sep 2026 |
| IG Mackenzie Global Sci &Tech C | 295K | 0.09% | -23.34% | Jul 2026 |
| Vanguard Health Care ETF | 269K | 0.08% | +0.11% | Sep 2026 |
| VictoryShares Small Cap Fr CA Flw ETF | 258K | 0.08% | +0.31% | Oct 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 238K | 0.07% | 0.00% | Oct 2026 |
| Distillate Small/Mid Cash Flow ETF | 221K | 0.06% | 0.00% | Aug 2026 |
| WisdomTree US SmallCap Earnings ETF | 182K | 0.05% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 178K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 172K | 0.05% | -0.05% | Sep 2026 |
Top institutions holding GDRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Francisco Partners Management LP | 60.1M | 17.61% | 0.00% | Jun 2026 |
| LSV Asset Management | 5.16M | 1.51% | +3.51% | Jun 2026 |
| Ameriprise Financial Inc | 4.75M | 1.39% | +6.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.09M | 1.20% | -4.11% | Jun 2026 |
| SILVER LAKE GROUP, L.L.C. | 3.53M | 1.04% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.38M | 0.99% | +32.10% | Sep 2026 |
| Renaissance Technologies Corp | 3.25M | 0.95% | -0.43% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.21M | 0.94% | -4.60% | Jun 2026 |
| Petrus Trust Company, LTA | 3.10M | 0.91% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 2.33M | 0.68% | +29.06% | Jun 2026 |
| Jane Street Group LLC | 2.31M | 0.68% | +257.07% | Jun 2026 |
| Prescott Group Capital Management LLC | 2.11M | 0.62% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.86M | 0.54% | -0.21% | Jun 2026 |
| Technology Crossover Management X, Ltd. | 1.65M | 0.48% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.17M | 0.34% | +8.65% | Jun 2026 |
| Northern Trust Corp | 904K | 0.27% | +38.03% | Jun 2026 |
| Stifel Financial Corp | 869K | 0.25% | +21.10% | Jun 2026 |
| Moore Capital Management, LP | 864K | 0.25% | -43.50% | Jun 2026 |
| The Goldman Sachs Group Inc | 858K | 0.25% | -18.87% | Jun 2026 |
| Two Sigma Investments LLC | 742K | 0.22% | +294.00% | Jun 2026 |
Goodrx Holdings Inc company profile
- Company name
- Goodrx Holdings Inc
- Ticker
- GDRX.US
- Exchange
- USA Stocks
- Listed since
- Sep 23, 2020
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 697
- Fiscal year end
- December
- Address
- 2701 Olympic Boulevard, Santa Monica, CA, United States, 90404
- Phone
- 855 268 2822
- Website
- goodrx.com
About Goodrx Holdings Inc
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Goodrx Holdings Inc management
10- Ms. Wendy BarnesPresident, CEO & Director · born 1973
- Mr. Douglas Joseph HirschCo-founder & Director · born 1971
- Mr. Justin FenglerChief Strategy & Operations Officer, CFO and Treasurer · born 1988
- Mr. Thomas ChanChief Accounting Officer & Principal Accounting · born 1986
- Mr. Nitin ShingateChief Technology Officer
- Ms. Aubrey ReynoldsDirector of Investor Relations
- Ms. Gracye ChengSenior VP, General Counsel & Secretary
- Ms. Vina M. LeiteChief People Officer · born 1970
- Mr. Scott PaulSenior Vice President of Healthcare & Consumer Innovation
- Mr. Aaron CrittendenChief Revenue Officer & President of Rx Marketplace